

## **PRESS RELEASE #11: AMICUS IN-LICENSES FURAZIDIN**

27th July, 2016

**Baar, Switzerland and Belgrade, Serbia: Amicus S.A. announces signature of Distributorship and Licensing Agreements with Genexo Sp. Z o. o. The agreement gives Amicus exclusive rights to register and launch furazadin in the countries of the Western Balkans – the EU countries of Croatia and Slovenia, and the EU accession countries of Serbia, Federation of Bosnia & Herzegovina, Macedonia and Montenegro.**

On June 30<sup>th</sup>, 2016 Amicus S.A. of Baar, Switzerland, and Genexo Sp. Z o. o. of Warsaw, Poland signed contracts under which Amicus will register, launch and market Genexo's originator compound furazidin (which would be a new compound launch in these countries for furazidin in urinary tract infections) in six countries of the the Western Balkans. The agreement provides for Amicus to exclusively commercialize Genexo's furazidin (sold under Furagin ® TM in other parts of CEE) for many years.

"This landmark agreement marks a departure for Amicus in that we are licensing-in and launching a compound new to our area, under our own TM. We are excited as furazidin has been extremely successful in other parts of CEE, is a proven product from safety, efficacy and commercial standpoints, and is competitively priced; it fits our markets perfectly. We will be registering and launching furazidin in the whole of the former Yugoslavia, under our own trademark. This will allow Amicus to substantially strengthen its position in the pharmacy, in urology and in gynecology across the Western Balkans," commented Jean-Michel Lespinasse, CEO of Amicus S.A. "We are proud to be given the opportunity to work with Genexo on this project, which supplements our growing collaboration on Genexo's differentiated consumer healthcare products Ci-Tri-Mag Forte ® and Prel ®, continued Lespinasse. We thank Genexo for its expression of confidence in Amicus, and we look forward to making furazidin a success in this region of more than 22 million people."

Under the agreement, Amicus' six affiliates in the territory will register, commercialize, promote and provide medical support to the healthcare sector regarding this molecule.

### **About Genexo**

Genexo is a privately-held, independent Polish pharmaceutical company based in Warsaw, Poland. A young and dynamic company, Genexo started its operations in 2004, and has sales of more than 30 million Euros. Genexo is one of Poland's market leaders in diabetic care and OTC & Food Supplements (self-care). Genexo attaches great importance to the quality of its products, all of which are based on differentiated, modern solutions and innovative technologies.

For more information about Genexo, please visit [www.genexo.pl](http://www.genexo.pl)

### **About Amicus S.A.**

Amicus subsidiaries operate in the Balkan and Baltic countries of Croatia, Estonia, Kosovo, Latvia, Lithuania, Macedonia, Montenegro, Serbia and Slovenia. Set up in 2014, Amicus has gathered outstanding pharmaceutical, Medical Device and also OTC / consumer healthcare talent. The company specializes in representing research-based pharmaceutical, medical equipment and brand self-care brands across the West Balkans and Baltics.

For more info about Amicus, please visit: [www.amicuspharma.eu](http://www.amicuspharma.eu)

### **Contact:**

**Maja Boskovic, Public Affairs Officer, Amicus**

Maja.Boskovic@amicuspharma.eu, Tel: +381 11 4426 321